Any current/future capex/capital investment/strategic investment?

The company is focused on enhancing operational efficiency both in the field and backend, indicating ongoing investments to improve productivity (Page 5). There is a mention of gearing up to launch new and modified products in Animal Healthcare and Pet Care divisions, which may require capital allocation for product development and marketing (Page 5). Hester Africa plant has 6 registered vaccines, with 5 more vaccines in the registration process by the end of the financial year, indicating investment in regulatory and market expansion efforts (Page 4). The harmonization of the vaccine registra

Future growth expectations in sales/revenue/volumes?

Focus on improving profitability and bottom line through operational efficiency and product mix rationalization. Expansion of sales in Africa with expectation of registration of additional products and increased exports. Launch of upgraded products like line extensions under Protein C in Animal Healthcare and modified Newcastle Disease Vaccine targeting better performance. Growth in Pet Care division, driven by expansion into Tier 2 and Tier 3 cities. Recovery expected in exports and poultry industry which had impacted recent sales. New health products launched (CuRx LA and substitute for iSum

Future growth expectations in earnings/operating earnings/profits/EPS?

Hester Biosciences aims to improve profitability and return to earlier EBITDA margin levels (~35%) within 2-3 years by enhancing sales efficiency and gaining traction in new segments. The company expects normalized margins to recover despite investments in pet care and setbacks in Nepal and Africa. Growth will be driven by expansion in health products, pet care (especially tier 2 and 3 cities), and increased exports, particularly from Africa as more vaccines get registered. New product launches, including line extensions in Animal Healthcare and Pet Care divisions, are expected to boost

Current/ Expected Orderbook/ Pending Orders?

The company did not explicitly mention the exact current or expected order book size during the call. However, they highlighted a few key ongoing and upcoming orders: - Supply of 30 crore doses of CPR vaccine as part of the national immunization program, expected to be completed by October 2024. - Distribution of 3 to 3.5 crore doses of goat pox vaccine for the lumpy skin disease immunization over the next two quarters. They indicated a strong focus on government tenders, especially for PPR and GPV vaccines, contributing to growth. There is an ongoing registration process for vaccines in A

Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned new fundraising through debt or equity in the transcript. The management discussed existing loans, especially dollar loans taken by the African subsidiary, resulting in higher finance costs due to currency fluctuations. The CFO indicated that the recent jump in finance costs is a one-time event and not expected to continue at the same high level, but future finance costs might be slightly higher than earlier quarters. The focus appears to be on improving profitability and operational efficiency rather than raising new capital. No direct co

IN US

Sale is live|00:00:00left today

Hester Biosciences LtdQ3 FY23Pharmaceuticals & Biotechnology

Hester Biosciences Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,953P/E: 38.0Market Cap: ₹1.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Focus on improving profitability and bottom line through operational efficiency and product mix rationalization.
→Expansion of sales in Africa with expectation of registration of additional products and increased exports.
→Launch of upgraded products like line extensions under Protein C in Animal Healthcare and modified Newcastle Disease Vaccine targeting better performance.
→Growth in Pet Care division, driven by expansion into Tier 2 and Tier 3 cities.
→Recovery expected in exports and poultry industry which had impacted recent sales.
→New health products launched (CuRx LA and substitute for iSumovet) to recoup loss due to withdrawal of earlier products.
→Continued emphasis on government tenders for vaccines like PPR and GPV contributing to steady sales.
→Anticipated increase in vaccine sales through national immunization programs (e.g., Lumpy Skin Disease and CPR vaccine).
→Management aims to reach earlier higher EBITDA margins within 2-3 years by gaining traction and efficiency.

Margin guidance

Category 3

→Hester Biosciences aims to improve profitability and return to earlier EBITDA margin levels (~35%) within 2-3 years by enhancing sales efficiency and gaining traction in new segments.
→The company expects normalized margins to recover despite investments in pet care and setbacks in Nepal and Africa.
→Growth will be driven by expansion in health products, pet care (especially tier 2 and 3 cities), and increased exports, particularly from Africa as more vaccines get registered.
→New product launches, including line extensions in Animal Healthcare and Pet Care divisions, are expected to boost sales.
→Recovery in exports and poultry industry conditions is anticipated, aiding revenue and margin improvement in H2 FY24.
→Currency fluctuation-related finance costs are expected to moderate from current elevated levels, supporting bottom-line improvement.
→Overall, management is confident of improving operating profits backed by execution on strategic goals and market expansion.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned new fundraising through debt or equity in the transcript.
→The management discussed existing loans, especially dollar loans taken by the African subsidiary, resulting in higher finance costs due to currency fluctuations.
→The CFO indicated that the recent jump in finance costs is a one-time event and not expected to continue at the same high level, but future finance costs might be slightly higher than earlier quarters.
→The focus appears to be on improving profitability and operational efficiency rather than raising new capital.
→No direct comments or guidance were provided about raising additional funds through debt or equity in the near term.

Order book

→The company did not explicitly mention the exact current or expected order book size during the call.
→However, they highlighted a few key ongoing and upcoming orders:
→ - Supply of 30 crore doses of CPR vaccine as part of the national immunization program, expected to be completed by October 2024.
→ - Distribution of 3 to 3.5 crore doses of goat pox vaccine for the lumpy skin disease immunization over the next two quarters.
→They indicated a strong focus on government tenders, especially for PPR and GPV vaccines, contributing to growth.
→There is an ongoing registration process for vaccines in African countries expected to enable prompt marketing and sales.
→New health product launches (CuRx LA and iSumovet substitutes) are planned to offset sales loss, implying anticipated new orders in coming quarters.

Capex plans

Yes

→The company is focused on enhancing operational efficiency both in the field and backend, indicating ongoing investments to improve productivity (Page 5).
→There is a mention of gearing up to launch new and modified products in Animal Healthcare and Pet Care divisions, which may require capital allocation for product development and marketing (Page 5).
→Hester Africa plant has 6 registered vaccines, with 5 more vaccines in the registration process by the end of the financial year, indicating investment in regulatory and market expansion efforts (Page 4).
→The harmonization of the vaccine registration process in Africa is expected to enable quicker market entry, suggesting strategic investment to facilitate business growth (Page 4).
→No explicit mention of large-scale capex or major capital investments was made in the transcript for the current or near future period. The focus seems more on product launches and operational improvements.

How does Hester Biosciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Hester Biosciences Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Hester Biosciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio